Search - tctmd.com

Displaying 941 - 960 of 1949

Sort: Relevancy | Date

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Martin B. Leon

October 30, 2016

Presentation TCT 2016

Hypertension Treatment Targets Beyond the Kidneys

Presenter: Felix Mahfoud, Michael A. Weber, Atul Pathak

October 30, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Presentation TCT 2016

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Aaron Chalekian

October 30, 2016

Presentation TCT 2016

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Presenter: Felix Mahfoud, Michael A. Weber, Michael Joner

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Presenter: Patrick T. O'Gara, Alec S. Vahanian, John G. Webb

October 30, 2016

Presentation TCT 2016

Points to Consider in the Review of Endovascular Treatment Devices: US Regulatory View

Presenter: Schuyler Jones, Misti Malone, Eleni Whatley

October 30, 2016

Presentation TCT 2016

Animal Testing: Real-World Experiences and Translational Challenges

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Presentation TCT 2016

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Presenter: Patrick T. O'Gara, Alec S. Vahanian

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Animal Testing: FDA Expectations

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu, Natalie Miller

October 30, 2016

Presentation TCT 2016

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Presenter: Felix Mahfoud, Michael A. Weber, Ehtisham Mahmud

October 30, 2016

Presentation TCT 2016

Points To Consider in the Review of Endovascular Treatment Devices: Japanese Regulatory View

Presenter: Schuyler Jones, Misti Malone, Shin Iwamoto

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Catherine M. Otto

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Elazer R. Edelman, Juan F. Granada, Changfu Wu

October 30, 2016

Presentation TCT 2016

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Samir R. Kapadia

October 30, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Atherectomy

Presenter: Schuyler Jones, Misti Malone, Brad Martinsen, PhD

October 30, 2016

Advertisement

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Real-world Requirements and Expectations for TAVR in Lower Risk Patients

Hypertension Treatment Targets Beyond the Kidneys

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Transcatheter Mitral Replacement Devices: An Update from the International Organization for Standardization (ISO) Cardiac Valves Committee

The Renal Nerves and Their Role in Hypertension: An Updated Synthesis (Anatomy and Pathophysiology)

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Flash Debate: Counterpoint - Guidelines Have Limited Value in Rapidly Evolving Transcatheter Valve Therapies!

Points to Consider in the Review of Endovascular Treatment Devices: US Regulatory View

Animal Testing: Real-World Experiences and Translational Challenges

Flash Debate: Point Guidelines Should Remain the Standard for Clinical Practice!

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Animal Testing: FDA Expectations

Is There a Role for PCI of Renal Artery Stenosis in Hypertension Management?

Points To Consider in the Review of Endovascular Treatment Devices: Japanese Regulatory View

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

An Interesting Alternative: The New WikiRecs for TAVR Use in Lower Risk Patients

FDA Perspectives

Future TAVR Guidelines: The Next ACC/AHA TAVR Focused Update and New Appropriate Use Criteria for TAVR

Overview of the Clinical Trials for Atherectomy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content